All-oral ixazomib, cyclophosphamide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma.

[1]  S. Lonial,et al.  A phase I/II dose-escalation study investigating all-oral ixazomib-melphalan-prednisone induction followed by single-agent ixazomib maintenance in transplant-ineligible newly diagnosed multiple myeloma , 2018, Haematologica.

[2]  M. Dimopoulos,et al.  Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma. , 2018, Blood.

[3]  P. Moreau,et al.  Ixazomib-Lenalidomide-Dexamethasone (IRd) Combination before and after Autologous Stem Cell Transplantation (ASCT) Followed By Ixazomib Maintenance Is a Safe and Effective Strategy in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Phase 2 Study from the Intergroupe Francophone Du MyéLome ( , 2017 .

[4]  A. Larocca,et al.  Elderly patients with multiple myeloma: towards a frailty approach? , 2017, Current opinion in oncology.

[5]  Sin-Ho Jung,et al.  Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  J. Berenson,et al.  A Multicenter, Open‐Label, Phase 1b Study of Carfilzomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients (CHAMPION‐2) , 2017, Clinical lymphoma, myeloma & leukemia.

[7]  H. Goldschmidt,et al.  Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  S. Tuchman,et al.  Phase II study of dose-attenuated bortezomib, cyclophosphamide and dexamethasone ("VCD-Lite") in very old or otherwise toxicity-vulnerable adults with newly diagnosed multiple myeloma. , 2017, Journal of geriatric oncology.

[9]  C. Hofmeister,et al.  Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology. , 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

[10]  M. Dimopoulos,et al.  Phase 3 Study (CLARION) of Carfilzomib, Melphalan, Prednisone (KMP) v Bortezomib, Melphalan, Prednisone (VMP) in Newly Diagnosed Multiple Myeloma (NDMM) , 2017 .

[11]  H. Goldschmidt,et al.  International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  A. Palumbo,et al.  Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. , 2016, The New England journal of medicine.

[13]  A. Dispenzieri,et al.  Treatment outcomes, health-care resource utilization and costs of bortezomib and dexamethasone, with cyclophosphamide or lenalidomide, in newly diagnosed multiple myeloma , 2016, Leukemia.

[14]  Michael L. Wang,et al.  Maintenance Therapy With Immunomodulatory Drugs in Multiple Myeloma: A Meta-Analysis and Systematic Review. , 2016, Journal of the National Cancer Institute.

[15]  P. Neri,et al.  Bortezomib-containing regimens (BCR) for the treatment of non-transplant eligible multiple myeloma , 2015, Annals of Hematology.

[16]  M. Dimopoulos,et al.  Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  J. Mary,et al.  Phase 1/2 study of carfilzomib plus melphalan and prednisone in patients aged over 65 years with newly diagnosed multiple myeloma. , 2015, Blood.

[18]  Neeraj Gupta,et al.  Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study. , 2014, The Lancet. Oncology.

[19]  Christian Jacques,et al.  Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. , 2014, The New England journal of medicine.

[20]  P. Sonneveld,et al.  Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study. , 2014, Blood.

[21]  M. Boccadoro,et al.  Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  I. Flinn,et al.  Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. , 2012, Blood.

[23]  M. Beksac,et al.  Continuous lenalidomide treatment for newly diagnosed multiple myeloma. , 2012, The New England journal of medicine.

[24]  R. Fonseca,et al.  A comparison of lenalidomide/dexamethasone versus cyclophosphamide/lenalidomide/dexamethasone versus cyclophosphamide/bortezomib/dexamethasone in newly diagnosed multiple myeloma , 2012, British journal of haematology.

[25]  G. Morgan,et al.  Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). , 2011, Blood.

[26]  Bin Jiang,et al.  Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. , 2008, The New England journal of medicine.

[27]  B. Barlogie,et al.  International uniform response criteria for multiple myeloma , 2006, Leukemia.